BTK and B-cell chronic lymphocytic leukemia: The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, is well established in the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL) [1–3].